论文部分内容阅读
将 3 2例 2型糖尿病患者随机分为安慰剂组和治疗组 (阿卡波糖治疗组 ) ,测定各指标。结果 :治疗前两组一般资料和血糖、血脂、HbA1c及 2 4小时尿微量白蛋白水平均无明显差异。三月后 ,治疗组的BMI、FPG、2hPG、TG、TC、HbA1c、2 4小时尿微量白蛋白水平均降低 ,与安慰剂组、服药前比较差异具有显著性。相关分析提示 2 4小时尿微量白蛋白水平与 2hPG、HbA1c和TG呈正相关 (r分别为 0 64、0 72、0 60 ,P <0 0 5 )。结论本研究显示 ,阿卡波糖可降低 2型糖尿病患者的 2 4小时尿微量白蛋白水平 ,对 2型糖尿病肾脏病变的防治有积极作用
32 patients with type 2 diabetes were randomly divided into placebo group and treatment group (acarbose treatment group), measured the indicators. Results: There was no significant difference between the two groups before treatment and the blood glucose, blood lipid, HbA1c and 24-hour urine microalbumin levels. After March, the levels of BMI, FPG, 2hPG, TG, TC, HbA1c, and 24-hour urine microalbuminuria in the treatment group were all decreased. Compared with the placebo group, the difference was significant before treatment. Correlation analysis showed that 24-hour urine microalbumin level was positively correlated with 2hPG, HbA1c and TG (r = 0 64,0 72,060 respectively, P <0 05). Conclusions This study shows that acarbose reduces 24-hour urine microalbuminuria in type 2 diabetic patients and has a positive effect on the prevention and treatment of type 2 diabetic nephropathy